EVPL

Across TCGA pan-cancer cohorts, EVPL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EVPL data layer compared with 20 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EVPL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EVPL expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and UCEC are the cancer types where EVPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.899	0.590	.001	39	view →
CCRCC	DFS	Quartile	All	0.940	0.265	.010	13	view →
UCEC	OS	Tertile	All	1.000	0.871	.009	6	view →
LUAD	DFS	Median	III,IV	0.305	0.702	.021	4	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EVPL–HNSC (OS)

Open the HNSC breakdown →